Mikhail Kalinichev - Addex Therapeutics Head Science
| ADXN Stock | CHF 0.06 0 1.75% |
Insider
Mikhail Kalinichev is Head Science of Addex Therapeutics
| Age | 55 |
| Phone | (41) 22 884 15 56 |
| Web | www.addexpharma.com |
Addex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8786) % which means that it has lost $0.8786 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0267) %, meaning that it generated substantial loss on money invested by shareholders. Addex Therapeutics' management efficiency ratios could be used to measure how well Addex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| Marc MD | Basilea Pharmaceutica AG | 59 | |
| Kaspar Mueller | Evolva Holding SA | 60 | |
| FCMA CGMA | Santhera Pharmaceuticals Holdin | 60 | |
| Laurenz Kellenberger | Basilea Pharmaceutica AG | 56 | |
| Roberto Galli | Newron Pharmaceuticals SpA | N/A | |
| Philipp Frech | Evolva Holding SA | N/A | |
| Ngo Nhan | COSMO Pharmaceuticals SA | 44 | |
| Davide Malavasi | COSMO Pharmaceuticals SA | 50 | |
| Marco Caremi | Newron Pharmaceuticals SpA | 66 | |
| Eva Kalias | Santhera Pharmaceuticals Holdin | N/A | |
| Marco Lecchi | COSMO Pharmaceuticals SA | 59 | |
| Ravi Anand | Newron Pharmaceuticals SpA | 66 | |
| Lutz Wevelsiep | Basilea Pharmaceutica AG | N/A | |
| Stefan Weber | Newron Pharmaceuticals SpA | 58 | |
| Thomas Meier | Santhera Pharmaceuticals Holdin | 61 | |
| Oliver Strub | Santhera Pharmaceuticals Holdin | 60 | |
| Dario Eklund | Santhera Pharmaceuticals Holdin | 55 | |
| Marc Schrader | Santhera Pharmaceuticals Holdin | N/A | |
| Peer Schroder | Basilea Pharmaceutica AG | N/A | |
| Dietrich Stber | Basilea Pharmaceutica AG | N/A | |
Management Performance
| Return On Equity | -2.03 | |||
| Return On Asset | -0.88 |
Addex Therapeutics Leadership Team
Elected by the shareholders, the Addex Therapeutics' board of directors comprises two types of representatives: Addex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Addex. The board's role is to monitor Addex Therapeutics' management team and ensure that shareholders' interests are well served. Addex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Addex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Dyer, CEO CoFounder | ||
| Werner Henrichi, Consultant | ||
| Mikhail Kalinichev, Head Science | ||
| JeanPhilippe Rocher, Head Chemistry | ||
| Roger MD, Chief Director | ||
| Lnaic Teyssdou, Head Fin | ||
| Robert Lutjens, Head Biology |
Addex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Addex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.03 | |||
| Return On Asset | -0.88 | |||
| Operating Margin | (17.07) % | |||
| Current Valuation | 2.92 M | |||
| Shares Outstanding | 115.35 M | |||
| Shares Owned By Insiders | 8.96 % | |||
| Shares Owned By Institutions | 9.31 % | |||
| Price To Earning | 39.53 X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 9.82 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Addex Stock Analysis
When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.